ILMN
Illumina Inc
NASDAQ · Life Sciences Tools & Services
$119.72
-13.89 (-10.40%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 4.25B | 4.33B | 13.97B | 13.33B | 12.49B |
| Net Income | 832.56M | 762.88M | 643.45M | 605.16M | 765.33M |
| EPS | — | — | — | — | — |
| Profit Margin | 19.6% | 18.6% | 4.6% | 4.5% | 6.1% |
| Rev Growth | -1.8% | -1.8% | +14.5% | +5.0% | +10.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 3.86B | 3.86B | 4.69B | 4.55B | 4.57B |
| Total Equity | 5.29B | 5.29B | 12.32B | 12.46B | 13.70B |
| D/E Ratio | 0.73 | 0.73 | 0.38 | 0.36 | 0.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 737.55M | 713.37M | 1.41B | 1.40B | 1.33B |
| Free Cash Flow | — | — | 414.74M | 480.17M | 566.05M |